Filing Flows › Jazz Pharmaceuticals (JAZZ) › Guidance & outlook
Jazz Pharmaceuticals (JAZZ) guidance and outlook
Jazz Pharmaceuticals (JAZZ) raised its guidance on Nov 2, 2026: Revenue $4.8B for FY2026; Gross margin 89%–90% for FY2026; Tax rate 20%–30% for FY2026. Jazz Pharmaceuticals' 10-Q filed Nov 2, 2026 makes 42 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $4.8B | raised |
| Gross margin | FY2026 | 89%–90% | reaffirmed |
| Tax rate | FY2026 | 20%–30% | raised |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 2, 2026
- We seek to identify and develop highly differentiated therapies for these patients that we expect will be long-lived assets and that we can support with an efficient commercialization model.
- Through Project Orbis, we completed applications of Ziihera for the same indication to MHRA and Health Canada.
- We are increasingly leveraging our internal R&D function, and we have entered into collaborations with third parties for the R&D of innovative early-stage product candidates and have supported additional investigator-sponsored trials that are anticipated to generate further data related to our products.
- We also seek out investment opportunities in support of the development of early- and mid-stage technologies in areas where we have deep expertise with a focus on validated targets and mechanisms.
- Below is a summary of our key ongoing and planned development projects related to our products and pipeline and their corresponding current stages of development:
- Our current 2026 operating plan assumes that Xywav, with 92% lower sodium compared to high-sodium oxybates (depending on the dose), a dosing titration option and an absence of a sodium warning, will remain the #1 branded oxybate treatment for narcolepsy; the position it held based on revenue in the third quarter of 2026, and the only FDA-approved therapy for IH .
- While we expect that our business will continue to meaningfully depend on Xywav revenues, there is no guarantee that Xywav revenues will remain at current levels.
- We expect to face intensifying branded competition in narcolepsy type 1 from Takeda's recently approved Orzeyful upon launch, the first FDA-approved oral orexin 2 receptor agonist, and future competition from other alternative products and clinical-stage orexin 2 receptor agonists currently in development for narcolepsy type 1, narcolepsy type 2 and IH.
- In the future, we expect our oxybate products to continue to face competition from generic versions of high-sodium oxybate pursuant to settlement agreements we entered into with multiple ANDA filers.
- payors to agree to higher rebates, deeper discounts, or restrictive pricing terms in response to these request for proposal cycles, and we cannot guarantee we will be able to agree to commercially reasonable terms with PBMs, or similar organizations and other third party payors, or that we will be able to ensure unrestricted patient access and preferred acceptance on formularies.
- Our financial condition, results of operations and growth prospects are also dependent on our ability to maintain or increase sales of Epidiolex/Epidyolex in the U.S. and Europe, which is subject to many risks and there is no guarantee that we will be able to continue to successfully commercialize Epidiolex/Epidyolex for its approved indications.
- Moreover, we expect that Epidiolex will face competition from generic products in the future.
Jazz Pharmaceuticals' latest quarter
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
Questions
Did Jazz Pharmaceuticals raise or lower its guidance?
Jazz Pharmaceuticals (JAZZ) raised its guidance on Nov 2, 2026: Revenue $4.8B for FY2026; Gross margin 89%–90% for FY2026; Tax rate 20%–30% for FY2026.
What does Jazz Pharmaceuticals expect?
We seek to identify and develop highly differentiated therapies for these patients that we expect will be long-lived assets and that we can support with an efficient commercialization model. Through Project Orbis, we completed applications of Ziihera for the same indication to MHRA and Health Canada. We are increasingly leveraging our internal R&D function, and we have entered into collaborations with third parties for the R&D of innovative early-stage product candidates and have supported additional investigator-sponsored trials that are anticipated to generate further data related to our pro
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.